EUROPEAN PATENT OFFICE U.S. PATENT AND TRADEMARK OFFICE

CPC NOTICE OF CHANGES 118

SEPTEMBER 1, 2015

PROJECT DP0054

The following classification changes will be effected by this Notice of Changes:

Action*	Subclass	Group(s)
Modified Definition (no frozen (F)symbol	A61K	39/00
definitions should be deleted):		

No other subclasses/groups are impacted by this Notice of Changes.

This Notice of Changes includes the following [Check the ones included]:
 CLASSIFICATION SCHEME CHANGES

 A. New, Modified or Deleted Group(s)

B. New, Modified or Deleted Warning Notice(s)

C. New, Modified or Deleted Note(s)

D. New, Modified or Deleted Guidance Heading(s)

2. DEFINITIONS (New or Modified)

A. DEFINITIONS (Full definition template)

B. DEFINITIONS (Definitions Quick Fix)

3. REVISION CONCORDANCE LIST (RCL)

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

5. CROSS-REFERENCE LIST (CRL)

CPC NOTICE OF CHANGES 118

SEPTEMBER 1, 2015

PROJECT DP0054

2. B. DEFINITIONS QUICK FIX

Symbol	Location of change (e.g., section title)	Existing reference symbol or text	Action; New symbol; New text
A61K39/00	Relationship Between Large Subject Matter Areas		New: Gene therapy: An appropriate A61K39/00 symbol is given when the in vivo expression of a protein arising from the delivery of a nucleic acid encoding the protein, and the generation of an immune response against the encoded protein results in a prophylactic or therapeutic effect. The same applies for the use of cells modified to produce a specific antigen/antibody, for use in gene therapy. An A61K48/00 symbol may also be given, if applicable, as specified under the A61K48/00 section definitions

NOTES:

- The table above is used for corrections or modifications to existing definitions, e.g. delete an entire definition or part thereof; propose new wording or modify wording of a section, change the symbol the definition is associated with, change or delete a reference symbol, etc.
- Do not delete (F) symbol definitions.